Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Inflammation × Pioglitazone × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 5 Insulin Resistance 3 Diabetes Mellitus, Type 2 3 Urinary Bladder Neoplasms 2 Pancreatic Neoplasms 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Carotid Intimal Medial Thickness 1 2 Skin Neoplasms 1 Pharmacokinetics of MDV3100 1 Neoplasm Metastasis 1 Meningioma 1 Memory Disorders 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Leukoplakia, Oral 1 Leukemia, Myeloid, Chronic-Phase 1 Inflammation 1 Head and Neck Neoplasms 1 Glioblastoma 1 Diabetes Mellitus 1 Cognitive Dysfunction 1 Carcinoma, Squamous Cell 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Exercise 5 Vitamin D 2 Tea 2 Sufentanil 2 Spironolactone 2 Oxycodone 2 Omeprazole 2 Metformin 2 Etanercept 2 Colchicine 2 ziprasidone 1 soybean oil, phospholipid emulsion 1 salicylsalicylic acid 1 ginger extract 1 falcarinol 1 falcarindiol 1 Zolpidem 1 Warfarin 1 Vecuronium Bromide 1 Vancomycin 1 Tranexamic Acid 1 Tobramycin 1 Sulindac 1 Sodium Salicylate 1 Sevoflurane 1 Sevelamer 1 Rocuronium 1 Riluzole 1 Resistance Training 1 Radiotherapy, Conformal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02689843 2019-11-12

AntiPCO

Shiraz University of Medical Sciences

Phase EARLY_PHASE1 Completed

Inflammation, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡